

OMB APPROVAL	
OMB Number:	3235-0104
Estimated average burden hours per response:	0.5

**INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>ARCH Venture Partners VII, LLC</u>  (Last) (First) (Middle) 8755 W. HIGGINS RD, SUITE 1025  (Street) CHICAGO IL 60631  (City) (State) (Zip)	2. Date of Event Requiring Statement (Month/Day/Year) 05/02/2018	3. Issuer Name and Ticker or Trading Symbol <u>Unity Biotechnology, Inc. [ UBX ]</u>	
		4. Relationship of Reporting Person(s) to Issuer (Check all applicable)  Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)	5. If Amendment, Date of Original Filed (Month/Day/Year)  6. Individual or Joint/Group Filing (Check Applicable Line)  <input type="checkbox"/> Form filed by One Reporting Person <input checked="" type="checkbox"/> Form filed by More than One Reporting Person

**Table I - Non-Derivative Securities Beneficially Owned**

1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	39,547	I	See Footnote <sup>(3)(5)</sup>

**Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)**

1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares			
Series A-1 Preferred Stock	(1)	(2)	Common Stock	2,030,625	(1)	I	See Footnote <sup>(3)(5)</sup>
Series A-2 Preferred Stock	(1)	(2)	Common Stock	4,228,432	(1)	I	See Footnote <sup>(3)(5)</sup>
Series B Preferred Stock	(1)	(2)	Common Stock	2,067,160	(1)	I	See Footnote <sup>(3)(5)</sup>
Series B Preferred Stock	(1)	(2)	Common Stock	1,486,745	(1)	I	See Footnote <sup>(4)(5)</sup>
Series C Preferred Stock	(1)	(2)	Common Stock	195,672	(1)	I	See Footnote <sup>(4)(5)</sup>

1. Name and Address of Reporting Person* <u>ARCH Venture Partners VII, LLC</u>  (Last) (First) (Middle) 8755 W. HIGGINS RD, SUITE 1025  (Street) CHICAGO IL 60631  (City) (State) (Zip)		
--	--	--

1. Name and Address of Reporting Person\*

[ARCH Venture Partners VII, L.P.](#)

(Last) (First) (Middle)  
8755 W. HIGGINS ROAD  
SUITE 1025

(Street)  
CHICAGO IL 60631

(City) (State) (Zip)

1. Name and Address of Reporting Person\*

[Arch Venture Fund VII LP](#)

(Last) (First) (Middle)  
8755 W HIGGINS  
SUITE 1025

(Street)  
CHICAGO IL 60631

(City) (State) (Zip)

1. Name and Address of Reporting Person\*

[ARCH Venture Partners VIII, LLC](#)

(Last) (First) (Middle)  
C/O ARCH VENTURE PARTNERS VIII, LLC  
8755 W. HIGGINS ROAD, SUITE 1025

(Street)  
CHICAGO IL 60631

(City) (State) (Zip)

1. Name and Address of Reporting Person\*

[ARCH Venture Fund VIII Overage, L.P.](#)

(Last) (First) (Middle)  
C/O ARCH VENTURE PARTNERS VIII, LLC  
8755 W. HIGGINS ROAD, SUITE 1025

(Street)  
CHICAGO IL 60631

(City) (State) (Zip)

1. Name and Address of Reporting Person\*

[NELSEN ROBERT](#)

(Last) (First) (Middle)  
C/O ARCH VENTURE PARTNERS  
8755 W. HIGGINS RD, SUITE 1025

(Street)  
CHICAGO IL 60631

(City) (State) (Zip)

1. Name and Address of Reporting Person*		
<a href="#">CRANDELL KEITH</a>		
(Last)	(First)	(Middle)
C/O ARCH VENTURE PARTNERS VIII, LLC 8755 W. HIGGINS ROAD, SUITE 1025		
(Street)		
CHICAGO	IL	60631
(City) (State) (Zip)		

1. Name and Address of Reporting Person*		
<a href="#">BYBEE CLINTON</a>		
(Last)	(First)	(Middle)
C/O ARCH VENTURE PARTNERS VIII, LLC 8755 W. HIGGINS ROAD, SUITE 1025		
(Street)		
CHICAGO	IL	60631
(City) (State) (Zip)		

**Explanation of Responses:**

1. The shares of the Issuer's Preferred Stock automatically convert into shares of the Issuer's Common Stock, for no additional consideration, on a 1:1 basis immediately prior to the consummation of the Issuer's initial public offering.
2. The expiration date is not relevant to the conversion of these securities.
3. The shares are directly held by ARCH Venture Fund VII, L.P. ("ARCH VII"). ARCH Venture Partners VII, L.P. (the "GPLP"), as the sole general partner of ARCH VII, may be deemed to beneficially own certain of the shares held by ARCH VII. ARCH Venture Partners VII, LLC ("GPLLC"), as the sole general partner of GPLP, may be deemed to beneficially own the shares held by GPLP. ARCH Partners VII and ARCH VII LLC disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
4. The shares are directly held by ARCH Venture Fund VIII Overage, L.P. ("ARCH Overage"). ARCH Venture Partners VIII, LLC (the "AVP GPLLC"), as the sole general partner of ARCH Overage, may be deemed to beneficially own the shares held by ARCH Overage. AVP GPLLC disclaims beneficial ownership of such shares, except to the extent of any pecuniary interest therein.
5. The managing directors of ARCH VII LLC and AVP GPLLC are Keith Crandell, Clinton Bybee and Robert Nelsen, and they may be deemed to beneficially own the shares held by ARCH Fund VII and ARCH Overage. Messrs. Crandell, Bybee and Nelsen disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

[ARCH Venture Fund VII, L.P.,  
By: ARCH Venture Partners  
VII, L.P., its General Partner,  
By: ARCH Venture Partners  
VII, LLC, its General Partner,](#) 05/02/2018  
[By: /s/ Mark McDonnell, as  
Attorney-in-Fact for Keith  
Crandell, Managing Director](#)

[ARCH Venture Fund VIII  
Overage, L.P., ARCH Venture  
Partners VIII, LLC, its General  
Partner, By: /s/ Mark  
McDonnell, as Attorney-in-  
Fact for Keith Crandell,  
Managing Director](#) 05/02/2018

[RCH Venture Partners VII,  
L.P., By: ARCH Venture  
Partners VII, LLC, its General  
Partner, By: /s/ Mark  
McDonnell, as Attorney-in-  
Fact for Keith Crandell,  
Managing Director](#) 05/02/2018

[ARCH Venture Partners VII,  
LLC, By: /s/ Mark  
McDonnell, as Attorney-in-  
Fact for Keith Crandell,  
Managing Director](#) 05/02/2018

[ARCH Venture Partners VIII,  
LLC, By: /s/ Mark  
McDonnell, as Attorney-in-  
Fact for Keith Crandell,  
Managing Director](#) 05/02/2018

<u>Keith Crandell, Managing Director, By: /s/ Mark McDonnell, as Attorney-in- Fact</u>	<u>05/02/2018</u>
<u>Clinton Bybee, Managing Director, By: /s/ Mark McDonnell, as Attorney-in- Fact</u>	<u>05/02/2018</u>
<u>Robert Nelsen, Managing Director, By: /s/ Mark McDonnell, as Attorney-in- Fact</u>	<u>05/02/2018</u>

\*\* Signature of Reporting Person      Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

**Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.**